Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy.
about
Targeting glutamate uptake to treat alcohol use disordersA Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensityPrediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validityTreatment options for sleep disturbances during alcohol recoveryThe pharmacotherapy of alcohol dependence: a state of the art review.Functional alterations in the dorsal raphe nucleus following acute and chronic ethanol exposure.Treatment of co-occurring anxiety disorders and substance use disorders.Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.Alcohol consumption and the use of antidepressants.Pharmacotherapy of alcohol use disorders: seventy-five years of progressA naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment.Role of the serotonergic system in alcohol dependence: from animal models to clinics.Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependenceEffects of alcoholism typology on response to naltrexone in the COMBINE study.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Type A/Type B Alcoholism Predicts Differential Response to Topiramate in a Smoking Cessation Trial in Dually Diagnosed Men.Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial.Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.Serotonergic Neuroplasticity in Alcohol Addiction.Typology of Substance Use Disorder Based on Temperament Dimensions, Addiction Severity, and Negative Emotions
P2860
Q27002488-32CE2FCB-4555-4D8A-BD7E-6559E22E22A9Q28068256-EB433B28-5DC8-4239-9E73-1011B90408CEQ30437148-91C7BFAB-CC02-4EAC-A7DF-9871CB277D9EQ30438482-B63B1796-BE02-4656-8A30-6495FA96B353Q30440516-1AFB40DF-0624-420F-AB5D-ACB9862AD106Q30440570-7E0A2827-0BA5-437B-928C-C722F16FEC21Q30447847-62E69231-513E-4572-8108-0D37E71217ABQ34115010-31421A88-3E00-484A-BD6B-573BAA862D7FQ34543952-5FFA4949-53DA-4B32-AECF-E36F68A181D3Q34906736-B2103470-7807-46B2-A36E-2100D84952C6Q35166440-66E0F9E6-4263-4B13-96AA-8E77797A794DQ35235473-5ABD225F-B06A-4D87-AEB2-99F55543D116Q35640952-D7E19FF7-3651-4E2C-A56B-022DE78412FEQ35677411-7639A914-F51B-4C27-A059-97FE90D9787EQ36337447-B3E2660E-B0F6-461A-86A6-ACD51B518F3AQ36429331-80ABF8CC-814A-42B4-BF7C-B7B51DBBEC52Q37040447-3ED0BFD5-19BC-41BC-9636-9794DC5810FEQ37060490-DADBD587-FE14-45C0-AF34-F2E9F9AFD498Q37404222-A457BB2A-0B10-44D1-B0E8-A13E566F5216Q38894904-C64D03B5-D4F3-4C8F-8AA9-E6D78BF8888CQ41551275-20F0571C-55FB-46BB-8B55-128BA1A65CDAQ49605183-E0E1FBB7-F2D1-45DA-A9E5-DB6A3373630FQ55032383-16BDBDC1-1089-4799-9D7B-4C61C0A1F16BQ57496461-DEAFD683-E6D6-4470-B0B4-D54543CABDA3
P2860
Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@ast
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@en
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@nl
type
label
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@ast
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@en
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@nl
prefLabel
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@ast
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@en
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@nl
P2093
P2860
P1476
Treatment outcomes in type A a ...... serotonergic pharmacotherapy.
@en
P2093
Craig Lipkin
Helen M Pettinati
Kevin G Lynch
William Dundon
P2860
P304
P356
10.1097/01.ALC.0000130974.50563.04
P577
2004-07-01T00:00:00Z